Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

Returns on capital

Crescent Biopharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-75.8%

avg -26.6%

ROIC

-74.6%

avg -72.7%

ROA

-64.1%

avg -59.7%

Analysis

ROA is currently the strongest return metric at -64.1% versus its period average of -59.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joshua T. Brumm

Chief Executive Officer & DirectorUSD 1.25M48271.76K0.99%

Jonathan McNeill

President & Chief Operating OfficerUSD 871.68K41134.59K0.49%

Ellie Im

Chief Medical OfficerUSD 847.84K48——

Wenjie Cheng

Senior Vice President of Technical Operations————

Christopher Doughty

Chief Business Officer—38——

Richard William Scalzo

Chief Financial Officer—4019.73K0.07%

Ryan Lynch

Senior Vice President of Finance, Treasurer & Chief Accounting Officer—4213.63K0.05%

Amy Reilly

Chief Communications Officer—52——

Barbara H. Bispham

General Counsel & Corporate Secretary—39——

Jan Pinkas

Chief Scientific Officer—5721.58K0.08%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

4

$30.61M

Sells

16

$1.51M

Net Transaction Value

+$29.10M

Net buying

Most Active

Fairmount Funds Management LLC

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 18, 26

Brumm Joshua T

Direct

Sell$131K
Sep 18, 26

McNeill Jonathan

Direct

Sell$64.1K
Sep 16, 26

Bispham Barbara Harlin

Direct

Sell$11.1K
Sep 16, 26

Brumm Joshua T

Direct

Sell$28.8K
Sep 16, 26

McNeill Jonathan

Direct

Sell$13.1K
Sep 16, 26

Im Ellie Eunkyung

Direct

Sell$11.2K
Sep 16, 26

Scalzo Richard William

Direct

Sell$10.2K
Sep 16, 26

Lynch Ryan

Direct

Sell$4.3K
Sep 16, 26

Pinkas Jan

Direct

Sell$11.8K
Jul 16, 26

Fairmount Funds Management LLC

Indirect

Buy$525.9

1–10 of 20

Summary

Insiders reported 4 buys worth $30.61M and 16 sells worth $1.51M over the last 12 months. That adds up to net buying of $29.10M. Fairmount Funds Management LLC was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+424.9%
+67.3% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +424.9% over three years. Forward estimates point to Revenue at +67.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Crescent Biopharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CBIO's management, answered from reported figures.

Who manages CBIO?

Crescent Biopharma, Inc. (CBIO) lists 10 active executives. The top listed executive is Jonathan McNeill, President & Chief Operating Officer.

Are CBIO insiders buying or selling?

Recent insider activity shows net buying of $46.84M.